AbstractmAs a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore highdose-intensity regimens in non-small-cell lung cancer. In a phase I study of weekly administration of cisplatin combined with oral etoposide we achieved a cisplatin dose intensity of 52. The prognosis for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) remains poor in spite of the continuous exploration of new cytotoxic drugs and the introduction of combined modality regimens. The impact of cisplatin-containing chemotherapy on survival is modest [29, 36, 38] . The meta-analysis of Donnadieu et al. [9] has shown that the response rate obtained with combinations of cisplatin with podophyllotoxins, vinca alkaloids, or ifosfamide and mitomycin C averages 34% in stage III disease but only 22% in metastatic disease. The combination of cisplatin and etoposide is widely used in NSCLC. Both drugs have only limited single-agent activity, with response rates varying from 8% to 30% [1 -4, 7, 10, 11, 28, 32, 35, 40] . The combination is suggested to be synergistic in cell lines as well as clinically [25, 37] . The activity and side effects of commonly applied schedules of this combination have been extensively described [22] .
In several tumor types a relationship has been suggested between the cisplatin dose intensity and the response rate or response duration [12, 13, 16, 31] . However, the results of prospective randomized studies addressing the issue of cisplatin dose intensity in NSCLC have not been conclusive [14, 16, 23] . The highest cisplatin dose intensity reached in these studies was 41 mg/m 2 per week [14] . In a phase I study exploring weekly administration of cisplatin combined with oral etoposide, we reached a higher median cisplatin dose intensity of 52.5 mg/m 2 per week [33] . In this schedule we made use of oral etoposide since its long-term administration is feasible and its activity has been demonstrated in various tumors, including NSCLC [17, 41] 25 µmol/l. Before the start of the treatment all patients had a full medical history and physical examination an ECG, a chest X-ray, computerized tomography (CT) of the chest and upper abdomen with and without i. v. contrast, and, if appropriate, clinical measurement of pathological lymph nodes or skin metastases. All patients underwent a neurological examination before the start of and after the completion of the cisplatin treatment and every 3 months thereafter.
During treatment, patients underwent a weekly physical examination; assessment of toxicity; full blood counts; determination of serum electrolyte, calcium, magnesium, and creatinine levels; liver-function tests; and determination of creatinine clearance. The response to treatment was assessed at 2 weeks after the last cisplatin administration. Standard WHO criteria were used for evaluation of response and toxicity [42] .
Treatment schedule
Cisplatin was infused at a dose of 70 mg/m 2 on days 1, 8, 15, and days 29, 36 and 43. Oral etoposide was given at a dose of 50 mg daily on days 1 -15 and 29 -43. During the cisplatin administration, patients were hospitalized for 24 h. The treatment regimen consisted of prehydration with 1000 ml dextrose-saline + 20 mmol KCL + 1 g MgSO4 over 4 h. Cisplatin powder was dissolved in 250 ml 3% NaCl and infused over 3 h, after which posthydration with 2 l dextrose-saline + 40 mmol KCl + 2 g MgSO4 was carried out over 8 h. As an antiemetic regimen, 8 mg ondansetron + 10 mg dexamethasone was given as a slow i. v. bolus directly before the start of the cisplatin infusion, and this treatment was repeated if necessary after 12 h. For delayed nausea and vomiting, metoclopramide was given at 20 mg t. i. d. orally or per suppository. Dose reductions were not allowed. If at the day of planned cisplatin administration the WBC was 5 2.5 × 10 9 /l and/or the platelet count was 5 75 × 10 9 /l, treatment was postponed until recovery to levels above these values, with the maximal delay being 2 weeks. In the case of a delay of 4 2 weeks or in the case of development of neuro-or nephrotoxicity of grade 2, patients had to be taken off study.
Patients responding to the treatment or showing stable disease at the first response evaluation were continued on treatment with oral etoposide at a dose of 50 mg/m 2 on days 1 -21 every 28 days for a maximum of four cycles. Etoposide was given as 50-mg soft gelatin capsules, and the dose was adjusted such that the dose delivered per treatment cycle deviated 5 5% from the planned dose. During the treatment with oral etoposide, patients underwent full blood counts every 2 weeks and determination of serum electrolytes as well as liverand renal-function tests every 4 weeks. Tumor response was evaluated every 8 weeks. A total of 54 patients were registered in the study. One patient was considered ineligible because of small-cell histology. Three patients were considered nonevaluable for response: one patient never started treatment, one patient had a protocol violation (too low a cisplatin dose), and one patient had concomitant radiotherapy on the indicator lesion. In all, 15 patients did not complete the planned treatment: 6 patients developed progressive disease, 2 patients had a treatment delay of 4 2 weeks due to leukocytopenia, 2 patients refused further treatment (1 after the first and 1 after the fourth cisplatin administration), 1 patient died of a myocardial infarction, 1 patient was taken off study because of the development of tinnitus after the second cisplatin cycle, 1 patient developed neutropenic fever, 1 patient had erysipelas, and 1 patient developed reversible cortical blindness after the fifth cisplatin cycle. These patients were considered treatment failures in the response analysis. Thus, 50 patients were evaluable for response and 47, for toxicity analysis. The patients' demographics are shown in Table 1 .
The 53 eligible patients received a total of 264 administrations of cisplatin, with the median being 6/patient (range 0 -6/patient). Reasons why the six planned cisplatin administrations were not completed are shown in Table 2 . Treatment delays of 1 week in 14 patients and of 2 weeks in 7 patients were necessary because of slow recovery of leukocytes and/or platelets. With the exception of the patient who developed neutropenic fever, leuko-and thrombocytopenia were not observed before the third cisplatin administration. Of the 35 patients who completed the planned treatment, 17 reached the planned cisplatin dose intensity of 60 mg/m 2 per week; 11 patients treated with a 1-week delay reached a dose intensity of 52.5 mg/m 2 per week; and 7 patients treated with a 2-week delay achieved a Of the 31 patients with stage IV disease, 29 were evaluable for response. Two patients were not evaluable: one patient never started treatment and one patient received too low a cisplatin dose. Nine patients showed a partial response (32%; 95% confidence interval 15 -49%) with a median duration of 28 weeks (range 16 -44 weeks). In all, 12 patients showed stable disease with a median duration of 18 weeks (range 12 -32 weeks). The median overall duration of survival for stage IV patients was 45 weeks (range 26 -106 weeks). The chance of achieving a response was equal for the histologic subtypes; of 21 evaluable patients with squamous-cell carcinoma, 12 showed a response versus 6/18 patients with adenocarcinoma and 2/7 patients with large-cell undifferentiated carcinoma (P = 0.29; Fisher's exact test). None of the patients with a performance status of 2 (all of whom had metastatic disease) responded.
Toxicity
The toxicity data are summarized in Table 3 . The worst toxicity per patient observed over the whole treatment period is shown according to WHO grade. For ototoxicity the Common Toxicity Criteria (CTC) grading scale was used [27] . Anemia was universal, with 38 patients developing 4 grade 1 anemia. A total of 30 patients required packed-red-cell transfusions for a total of 127 units. Grade 3+4 leukocytopenia was observed in 17 patients. Leukocytopenia was the main cause of treatment delay, mainly occurring on day 29, when the fourth cisplatin administration was planned. Only one patient developed neutropenic fever. There was no toxic death. Thrombocytopenia of grade 3 was observed in six patients and that of grade 4, in two patients. One patient required a platelet transfusion on one occasion. No hemorrhagic complication was observed.
All patients developed alopecia; nausea and vomiting was seldom observed during the first 3 weeks of the treatment but occurred frequently thereafter and was also frequently reported during the oral etoposide maintenance phase. A total of 20 patients lost 4 5% of their initial body weight, and 5 of these patients showed a weight loss of Numerous phase II and III studies have been performed in NSCLC over the last two decades and, nevertheless the discussion on "the best" regimen continues. The combination of cisplatin and etoposide is frequently used, and the response rate averages 30% [22] . Studies analyzing the results obtained in locally advanced disease separately report even higher response rates of up to 69% in this subset of patients [39] . Retrospective analyses of several tumor types have suggested that the dose intensity of chemotherapy may be important [8, 20] . However, the results of prospective randomized studies addressing cisplatin dose intensity in NSCLC are inconclusive. The first study was reported in 1981 by Gralla et al. [16] . In this study cisplatin at 120 mg/ m 2 was compared with cisplatin at 60 mg/m 2 , given every 4 weeks in combination with vindesine. The response rate was equal in the two arms (43%), but the response duration was superior in the high-dose arm as compared with the low-dose arm (12 versus 5.5 months) and the median survival of responders in the high-dose arm was more than double that of responders in the low-dose arm [16] . Klastersky et al. [23] compared cisplatin given at 120 versus 60 mg/m 2 in combination with etoposide every 3 -4 weeks and observed no difference in response rate or survival between the two treatment arms.
In the three-arm study of Gandara et al. [14] , cisplatin given as a single agent at 50 mg/m 2 on days 1 and 8 every 4 weeks was compared with single-agent high-dose cisplatin given at 100 mg/m 2 on days 1 and 8 versus cisplatin given at 100 mg/m 2 on days 1 and 8 plus mitomycin C given at 8 mg/m 2 on day 1 every 4 weeks. Only stage IV patients were included in this study. A response was observed in 12% of patients in the standard-dose arm and in 14% of those in the high-dose single-agent-cisplatin arm. In the high-dose arm with mitomycin C the response rate was 27%. Complete responders were observed only in the high-dose arms. Survival, however, did not differ between the treatment arms. The highest cisplatin dose intensity reached in these studies was 41 mg/m 2 per week [14] .
In a phase 1 study we have shown that with weekly administration of cisplatin a higher cisplatin dose intensity can be reached [33] . Weekly administration of chemotherapy also has the theoretical advantage that regrowth of sublethally damaged tumor cells should be hindered more effectively than in schedules with longer intervals. Studies performed in the 1970s with weekly administration of cisplatin showed activity in NSCLC and head and neck cancer but were not explored further because of toxicity [5, 34, 40] . With improved supportive measures, weekly administration of cisplatin has become feasible, which the present study again confirms: most patients reached a cisplatin dose intensity of 52.5 -60 mg/m 2 per week, and we observed a response in 32% of patients with stage IV disease and in 52% of those with stage III disease. This response rate is comparable with that reported for other "high-ranking" regimens [6, 39] .
Also as compared with other studies using frequent dosing of cisplatin in NSCLC, the dose intensity we achieved was high. Higano et al. [18] used cisplatin weekly at a dose of 50 mg/m 2 in combination with mitomycin C, vinblastine, and fluorouracil and reported a response in 23% of their patients, but these included only patients with distant metastases. The median dose intensity of cisplatin reached in their study was 40 -44 mg/m 2 per week [18] . O'Dwyer et al. [30] reported a phase II study of weekly cisplatin given at a dose of 30 mg/m 2 in combination with weekly 24-h infusions of fluorouracil and vinblastine. In all, 44% of their patients responded; however, the median duration of response was only 4 months [30] .
In general, the toxicity of our regimen was acceptable. Only one patient had neutropenic fever; there was no toxic death. Leukocytopenia and, to a lesser degree, thrombocytopenia were the most frequent causes of treatment delay, partly jeopardizing the dose-intensity concept. Only seven patients developed renal toxicity of grade 1; this low number may be related to the administration of cisplatin in hypertonic saline and to the vigorous hydration program. In Higano et al.'s study [18] , which also involved cisplatin administration in hypertonic saline, renal toxicity of grade 2 and higher was observed in only 6 of 77 patients. These results contrast with those of Vogl et al. [40] , who reported renal toxicity in 40% of 30 patients treated with cisplatin at 75 mg/m 2 on days 1, 8, 15 and every 3 weeks thereafter, with cisplatin being infused in dextrose-saline.
In all, 13 patients in our study developed neurotoxicity of grade 1; no patient developed grade 2 neurotoxicity, although most patients received a cumulative cisplatin dose of 420 mg/m 2 . All these patients were followed for 6 months, if possible, as it is known that neurotoxic signs may even worsen after the cessation of treatment [19] . Cortical blindness is a very seldom-reported manifestation of cisplatin neurotoxicity; a relationship to hypomagnesemia has been suggested [15] . Hypomagnesemia can lead to focal or generalized seizures, as we observed in another patient. However, on the day of visual loss, our patient had a normal serum magnesium level; he recovered completely. Ototoxicity of grade 2+3 was observed in 28% of our patients; this toxicity is common to high-dose cisplatin regimens. Kim et al. [21] used cisplatin at 180 mg/m 2 every 2 weeks in combination with sodium thiosulfate, thereby achieving a median cisplatin dose intensity of 79 mg/m 2 per week, and reported the development of a hearing loss in 9 of 19 patients. Gandara et al. [14] reported a 17% incidence of ototoxicity in the high-dose cisplatin arm of their study. As clinical hearing loss is irreversible, it now replaces classic cisplatin-induced toxicities such as nephro-and gastrointestinal toxicity in being dose-limiting. The response rate of 52% obtained in stage III disease, in our opinion, warrants further exploration of the present regimen in locally advanced NSCLC, and its combination with radiotherapy might be attractive provided that toxicity can be limited. Recently the Radiation Therapy Oncology Group [24] reported a study of cisplatin given at 50 mg/m 2 on days 1 and 8 in combination with oral etoposide given at 75 or 100 mg/day on days 1 -14 with concomitant hyperfractionated radiotherapy. The response rate of 70% was encouraging, but the toxicity, especially hematologic toxicity and esophagitis, was high [24] . Combination with chemoprotective agents (such as WR-2721 or sodium thiosulfate) could be of interest for these high-dose schedules. If they indeed have a protective effect against toxicity, randomized studies comparing highly dose-intensive regimens with standard-dose regimens in larger patient populations or their combination with radiotherapy would become possible. However, in our opinion, equal treatment results can be achieved in stage IV disease with less intense regimens.
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